5 months ago
MLYS
AnalystsGreg HarrisonGreg Harrison's Stock Forecasts
AnalystsGreg Harrison
Analyst Ranking
Top 7%
#320 out of 5186 analysts
Average Return
+26.95%
Win Rate
59%48 out of 81
Risk vs Reward
Poor
Good
Greg Harrison's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Iveric Bio IncISEE | +244.89% | $11.25 | $38.80 | 2022-06-07 - 2023-06-07 | Strong Buy |
Liquidia CorpLQDA | +203.63% | $14.18 | $43.04 | 2025-05-27 - 2026-02-06 | Buy |
Bridgebio Pharma IncBBIO | +179.89% | $23.72 | $66.39 | 2024-11-14 - 2025-11-14 | Buy |
Liquidia CorpLQDA | +178.76% | $15.44 | $43.04 | 2025-03-19 - 2026-02-06 | Buy |
Liquidia CorpLQDA | +167.00% | $16.12 | $43.04 | 2025-05-04 - 2026-02-06 | Buy |
Greg Harrison Analyst Color
Get additional color on Greg Harrison's coverage of popular stocks
3 years ago
NTLA
Greg Harrison's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Agios Pharmaceuticals IncAGIO | 9 | Strong Buy | $34.00 | +28.16% | Maintains | a month ago |
Intellia Therapeutics IncNTLA | 3 | Strong Buy | $30.00 | +144.30% | Maintains | 3 months ago |
United Therapeutics CorpUTHR | 4 | Hold | $463.00 | -4.61% | Maintains | 5 months ago |
Mineralys Therapeutics IncMLYS | 2 | Strong Buy | $43.00 | +44.44% | Maintains | 5 months ago |
Travere Therapeutics IncTVTX | 6 | Buy | $31.00 | +4.34% | Maintains | 6 months ago |
Ocular Therapeutix IncOCUL | 2 | Buy | $20.00 | +118.34% | Maintains | 6 months ago |
Bridgebio Pharma IncBBIO | 7 | Buy | $57.00 | -16.24% | Maintains | 6 months ago |
Vertex Pharmaceuticals IncVRTX | 7 | Hold | $438.00 | -8.35% | Maintains | 6 months ago |
Alnylam Pharmaceuticals IncALNY | 6 | Buy | $450.00 | +37.13% | Maintains | 6 months ago |
Gossamer Bio IncGOSS | 1 | Buy | $11.00 | +386.73% | Initiates Coverage On | 7 months ago |
Arcturus Therapeutics Holdings IncARCT | 2 | Buy | $35.00 | +362.35% | Maintains | 7 months ago |
Rocket Pharmaceuticals IncRCKT | 6 | Buy | $19.00 | +501.27% | Maintains | 8 months ago |
Liquidia CorpLQDA | 6 | Buy | $37.00 | -14.03% | Maintains | 8 months ago |
Keros Therapeutics IncKROS | 6 | Buy | $26.00 | +47.98% | Maintains | 9 months ago |
Vera Therapeutics IncVERA | 2 | Buy | $55.00 | +26.44% | Maintains | 9 months ago |
Apellis Pharmaceuticals IncAPLS | 4 | Hold | $20.00 | -14.86% | Maintains | 9 months ago |
Geron CorpGERN | 3 | Hold | $1.50 | -1.96% | Downgrades | 9 months ago |
Beam Therapeutics IncBEAM | 5 | Buy | $40.00 | +50.83% | Upgrades | a year ago |
Disc Medicine IncIRON | 4 | Buy | $75.00 | -5.92% | Maintains | a year ago |
Eyepoint Pharmaceuticals IncEYPT | 1 | Buy | $18.00 | N/A | Initiates Coverage On | a year ago |
Stoke Therapeutics IncSTOK | 3 | Hold | $12.00 | N/A | Upgrades | 3 years ago |
Sangamo Therapeutics IncSGMO | 1 | Sell | $1.50 | N/A | Downgrades | 3 years ago |
Editas Medicine IncEDIT | 2 | Hold | $15.00 | N/A | Maintains | 3 years ago |
Omeros CorpOMER | 1 | Sell | $3.00 | N/A | Downgrades | 3 years ago |
Senti Biosciences IncSNTI | 1 | Strong Buy | $70.00 | N/A | Initiates Coverage On | 3 years ago |
Neurogene IncNGNE | 2 | Sell | $5.00 | N/A | Downgrades | 3 years ago |
Radius Health IncRDUS1 | 1 | Hold | $8.00 | N/A | Upgrades | 4 years ago |
Iveric Bio IncISEE | 1 | Strong Buy | $18.00 | N/A | Initiates Coverage On | 4 years ago |
Athersys IncATHXQ | 4 | Sell | $6.25 | N/A | Downgrades | 4 years ago |
Sentinelone IncS | 1 | Strong Buy | $54.00 | N/A | Maintains | 4 years ago |
Nektar TherapeuticsNKTR | 5 | Sell | $90.00 | N/A | Downgrades | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.